Back to top
more

Shockwave Medical Inc. (SWAV)

(Delayed Data from NSDQ)

$43.43 USD

43.43
437,633

+2.29 (5.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $43.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates

Change Healthcare's (CHNG) fiscal first-quarter 2023 results benefit from solid performance across Software and Analytics, Network Solutions and Enterprise Imaging segments.

LHC Group (LHCG) Q2 Earnings & Revenues Miss Estimates

LHC Group's (LHCG) second-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.

Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat

Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.

McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates

McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.

Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.

Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.

Shockwave Medical (SWAV) Reports Next Week: Wall Street Expects Earnings Growth

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) Q2 Earnings Match Estimates, Revenues Miss

Despite the top line missing estimates, DexCom's (DXCM) second-quarter results reflected strong domestic and international revenue growth.

Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M

Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View

Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.

CONMED (CNMD) Down on In-Line Q2 Earnings & Lower 2022 View

CONMED's (CNMD) adjusted second-quarter earnings reflect strong segmental performance. However, unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.

Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut

Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.

Align Technology (ALGN) Q2 Earnings Lag Estimates, Margins Drop

The dull underlying market situation, impacted by macro-economic environmental factors and lingering effects of COVID-19 variants in certain markets, impacts Align Technology's (ALGN) Q2 results.

Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?

Style Box ETF report for IWM

Intuitive Surgical (ISRG) Q2 Earnings Miss, Procedures Recover

Intuitive Surgical's (ISRG) second-quarter results reflect health demand for procedures despite the resurgence of COVID-19 infections.

Here's Why You Should Hold On to DexCom (DXCM) Stock Now

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Centene (CNC) Divests Unit to Boost Focus on Core Business

Centene (CNC) closes the deal to divest its pharmacy business. CNC primarily intends to pursue share repurchases with proceeds received from the transaction.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Fresenius (FMS) Faces Fraud Accusation From US Government

The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.